Ovarian Histopathological Lesions by Superovulation Induction Drugs Intake in Female Rats

• Ibtihal K. Mazyed

  Department of Biology, College of Education for Pure Sciences, University of Thi-Qar, Thi-Qar

• Fatima A. Al-badry

  Department of Biology, College of Education for Pure Sciences, University of Thi-Qar, Thi-Qar

This study was conducted to determination the effects of fertility drugs on some sex hormones and the histological changes of the ovary. Forty-two of female rats were used, it divided into sevsn groups, each group containing 6 rats. The first group was fed with distilled water and feed as control group. The second and third groups were received Clomid (50 mg) for one month and two months respectively. The fourth and fifth groups were given Duphaston (10 mg) for one month and two months respectively.  The sixth and seventh groups were treated with the Procreation V for one and two months. The results showed a singnificant increasing in levels of sex hormones (estrogen, progesterone and prolactin) in addition to histological damage such as the decline of ovarian follicles with congestion, edema, fibrosis, bleeding, increasing thickness of germinal layers and inflammation, as it was found that exposure to them for a period of two months is the most harmful.

 Highlights:

1. Drugs increased estrogen, progesterone, and prolactin levels significantly.
2. Histological damage: follicle loss, inflammation, fibrosis, bleeding.
3. Two-month exposure caused the most severe ovarian harm.

Keywords: Fertility drugs, ovary, progesterone, histological lesions

[1]. A. Gupta and P. Deshpande, “Causes and prevalence of factors causing infertility in a public health facility,” Journal of Human Reproductive Sciences, vol. 12, no. 4, p. 287, Jan. 2019, doi: 10.4103/jhrs.jhrs_140_18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6937760/

[2]. M. A. Saleh, M. B. Al-Salahy, and S. A. Sanousi, “Oxidative stress in blood of camels (Camelus dromedaries) naturally infected with Trypanosoma evansi,” Veterinary Parasitology, vol. 162, no. 3–4, pp. 192–199, Apr. 2009, https://pmc.ncbi.nlm.nih.gov/articles/PMC10156784/

[3]. R. Jewelewicz and P. R. Gindoff, “Induction of Ovulation – Past, Present and Future,” Gynecologic and Obstetric Investigation, vol. 26, no. 2, pp. 89–103, Jan. 1988, https://doi.org/10.1159/000293679

[4]. R. Homburg, “Clomiphene citrate—end of an era? a mini-review,” Human Reproduction, vol. 20, no. 8, pp. 2043–2051, May 2005, doi: 10.1093/humrep/dei042. https://doi.org/10.1093/humrep/dei042

[5]. E. S. Jungheim and A. O. Odibo, “Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents,” Fertility and Sterility, vol. 94, no. 7, pp. 2659–2664, May 2010, doi: 10.1016/j.fertnstert.2010.03.077. https://doi.org/10.1016/j.fertnstert.2010.03.077

[6]. J. Reefhuis, M. A. Honein, L. A. Schieve, and S. A. Rasmussen, “Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005,” Human Reproduction, vol. 26, no. 2, pp. 451–457, Nov. 2010, doi: 10.1093/humrep/deq313. https://doi.org/10.1093/humrep/deq313

[7]. T. Nagao and S. Yoshimura, “Oral administration of clomiphene to neonatal rats causes reproductive tract abnormalities,” Birth Defects Research, vol. 21, no. 3, pp. 213–221, Jan. 2001, doi: 10.1002/tcm.1010. https://doi.org/10.1002/tcm.1010

[8]. H. F. Okab, M. B. Salih, and B. A. Jarulla, “Evaluation of CXCL 10 and IL-10 in COVID-19 pneumonia,” Pneumologia, vol. 71, no. 4, pp. 175–180, Dec. 2022, doi: 10.2478/pneum-2023-0043. https://doi.org/10.2478/pneum-2023-0043

[9]. A. T. Abdelhafiz and J. A. Muhamad, “Midcycle pericoital intravaginal bee honey and royal jelly for male factor infertility,” International Journal of Gynecology & Obstetrics, vol. 101, no. 2, pp. 146–149, Jan. 2008, https://doi.org/10.1016/j.ijgo.2007.11.012

[10]. W. Schoolcraft, E. Sinton, T. Schlenker, D. Huynh, F. Hamilton, DR. Meldrum. “Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate,” PubMed, Mar. 01, 1991. https://pubmed.ncbi.nlm.nih.gov/1900481/

[11]. S. K. Chaube, P. V. Prasad, V. Tripathi, and T. G. Shrivastav, “Clomiphene citrate inhibits gonadotropin-induced ovulation by reducing cyclic adenosine 3′,5′-cyclic monophosphate and prostaglandin E2 levels in rat ovary,” Fertility and Sterility, vol. 86, no. 4, pp. 1106–1111. http://dx.doi.org/10.1016/j.fertnstert.2006.03.027

[12]. Duran 3rd JR, Raja ML. Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report. The Journal of Reproductive Medicine. 2007 Nov 1;52(11):1059-62. https://pubmed.ncbi.nlm.nih.gov/18161408/

[13]. “Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis,” PubMed, Oct. 01, 1983. https://pubmed.ncbi.nlm.nih.gov/6578367/

[14]. M. Matalliotakis, I. Koliarakis, C. Matalliotaki, A. Trivli, and E. Hatzidaki, “Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: a brief review.,” PubMed, vol. 90, no. 1, pp. 149–157, Jan. 2019, https://www.ncbi.nlm.nih.gov/books/NBK507829/

[15]. I. Ozdemir, N. Ustundag, A. Guven, B. Duran, and F. Demirci, “Effect of clomiphene citrate on ovarian, endometrial, and cervical histologies in a rat model,” Gynecologic and Obstetric Investigation, vol. 60, no. 4, pp. 181–185, Jan. 2005, https://doi.org/10.1159/000086962

[16]. M. E. Carter and D. N. Joyce, “Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: A case report,” Journal of in Vitro Fertilization and Embryo Transfer, vol. 4, no. 2, pp. 126–128, Apr. 1987, https://doi.org/10.1007/bf01555453